Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer

被引：0
作者：
Makoto Natsume
Takaya Shimura
Hiroyasu Iwasaki
Yusuke Okuda
Mika Kitagawa
Yasuyuki Okamoto
Kazuki Hayashi
Hiromi Kataoka
机构：
[1] Nagoya City University Graduate School of Medical Sciences,Department of Gastroenterology and Metabolism
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 83卷
关键词：
Angiogenesis; Biomarker; Gastric cancer; PlGF; Ramucirumab; VEGF;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1037 / 1046
页数：9
相关论文
共 50 条
  • [31] Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices
    Paulson, A. Scott
    Hess, Lisa M.
    Liepa, Astra M.
    Cui, Zhanglin Lin
    Aguilar, Kathleen M.
    Clark, Jamyia
    Schelman, William
    GASTRIC CANCER, 2018, 21 (05) : 831 - 844
  • [32] Treatment with placental growth factor attenuates myocardial ischemia/reperfusion injury
    Zhang, Yabing
    Cao, Chang
    Xin, Juan
    Lv, Peilin
    Chen, Dongxu
    Li, Shiyue
    Yang, Hui
    Chen, Chan
    Liu, Bin
    Li, Qian
    PLOS ONE, 2018, 13 (09):
  • [33] Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer
    Fornaro, Lorenzo
    Musettini, Gianna
    Orlandi, Paola
    Pecora, Irene
    Vivaldi, Caterina
    Banchi, Marta
    Salani, Francesca
    Fini, Elisabetta
    Massa, Valentina
    Catanese, Silvia
    Cucchiara, Federico
    Lencioni, Monica
    Masi, Gianluca
    Vasile, Enrico
    Bocci, Guido
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (07): : 3347 - 3356
  • [34] Placental Growth Factor in Bladder Cancer Compared to the Diagnostic Accuracy and Prognostic Performance of Vascular Endothelial Growth Factor A
    Soukup, Viktor
    Capoun, Otakar
    Pesl, Michael
    Sobotka, Roman
    Vavrova, Lucie
    Hanus, Tomas
    Zima, Tomas
    Kalousova, Marta
    ANTICANCER RESEARCH, 2018, 38 (01) : 239 - 246
  • [35] Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer
    Kimura, Michio
    Usami, Eiseki
    Teramachi, Hitomi
    Yoshimura, Tomoaki
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (06) : 403 - 411
  • [36] Comparison of the prognostic effect of taxane regimens combined with ramucirumab before nivolumab for advanced gastric cancer
    Kikuchi, Yoshinori
    Oshima, Yoko
    Fujisaki, Muneharu
    Tsuru, Mao
    Urakami, Hidejiro
    Nagaoka, Sakae
    Futawatari, Nobue
    Yajima, Satoshi
    Shimada, Hideaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, : 1152 - 1161
  • [37] Expression of Hepatocyte Growth Factor and Basic Fibroblast Growth Factor as Prognostic Indicators in Gastric Cancer
    Zhang, Wei
    Chu, Yong-Quan
    Ye, Zai-Yuan
    Zhao, Zhong-Sheng
    Tao, Hou-Quan
    ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY, 2009, 292 (08): : 1114 - 1121
  • [38] Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?
    Takeshi Yamada
    Yoshiyuki Yamamoto
    Toshikazu Moriwaki
    Ichisnosuke Hyodo
    Journal of Gastroenterology, 2016, 51 : 506 - 507
  • [39] Sustained Placental Growth Factor-2 Treatment Does Not Aggravate Advanced Atherosclerosis in Ischemic Cardiomyopathy
    Wu, Ming
    Pokreisz, Peter
    Swinnen, Melissa
    Caluwe, Ellen
    Gillijns, Hilde
    Vanden Driessche, Nina
    Casazza, Andrea
    Verbeken, Erik
    Collen, Desire
    Janssens, Stefan
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2017, 10 (04) : 348 - 358
  • [40] Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents
    Kim, Hark Kyun
    Green, Jeffrey E.
    PHARMACOGENOMICS, 2014, 15 (03) : 375 - 384
12345